文献速递肝病消化道肿瘤与早癌

混合型肝细胞癌-胆管癌起源于肝祖细胞并依赖衰老及IL-6反式信号传导

Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling.
PubMed 文献 · J Hepatol · 2022-08-18

该研究在Mdr2基因敲除小鼠中利用Foxl1启动子驱动的YFP报告基因追踪肝祖细胞,发现肝祖细胞是混合型肝细胞癌-胆管癌(cHCC-CCA)的来源而非肝细胞癌(HCC)的来源;cHCC-CCA中IL-6信号通路富集,阻断IL-6反式信号传导或使用衰老细胞清除剂可抑制cHCC-CCA的发生发展。

要点

  • 肝祖细胞是cHCC-CCA肿瘤的来源,而非HCC的来源。
  • 清除肝祖细胞可减少cHCC-CCA肿瘤,但不影响HCC。
  • 抗IL-6抗体、阻断IL-6反式信号传导或衰老细胞清除剂均可抑制cHCC-CCA发展。

核心结论

  • cHCC-CCA而非HCC肿瘤起源于肝祖细胞,部分来源于衰老细胞的IL-6通过IL-6反式信号传导在此过程中起重要作用。

研究设计与样本

  • 研究使用携带Foxl1启动子驱动YFP报告基因的Mdr2敲除小鼠(Mdr2-KOFoxl1-CRE;RosaYFP),该模型在14-16月龄发生慢性炎症和HCC,18月龄后发生cHCC-CCA肿瘤。

主要发现

  • 在Mdr2-KOFoxl1-CRE;RosaYFP小鼠模型中,肝祖细胞是cHCC-CCA肿瘤的来源,但不是HCC的来源。
  • 清除肝祖细胞导致cHCC-CCA肿瘤减少,但未影响HCC。
  • RNA测序显示cHCC-CCA肿瘤中IL-6信号通路富集,单细胞RNA测序显示衰老期间免疫细胞和实质细胞表达IL-6,且IL-6是衰老相关分泌表型的一部分。
  • 给予抗IL-6抗体可抑制cHCC-CCA肿瘤的发生;阻断IL-6反式信号传导导致cHCC-CCA肿瘤数量和大小减少;给予衰老细胞清除剂抑制IL-6和cHCC-CCA肿瘤的发展。

临床怎么用

  • 作者认为这些发现可用于开发cHCC-CCA肿瘤的新治疗方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Primary liver cancers include hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (CCA) and combined HCC-CCA tumors (cHCC-CCA). It has been suggested, but not unequivocally proven, that hepatic progenitor cells (HPCs) can contribute to hepatocarcinogenesis. We aimed to determine whether HPCs contribute to HCC, cHCC-CCA or both types of tumors. METHODS: To trace progenitor cells during hepatocarcinogenesis, we generated Mdr2-KO mice that harbor a yellow fluorescent protein (YFP) reporter gene driven by the Foxl1 promoter which is expressed specifically in progenitor cells. These mice (Mdr2-KOFoxl1-CRE;RosaYFP) develop chronic inflammation and HCCs by the age of 14-16 months, followed by cHCC-CCA tumors at the age of 18 months. RESULTS: In this Mdr2-KOFoxl1-CRE;RosaYFP mouse model, liver progenitor cells are the source of cHCC-CCA tumors, but not the source of HCC. Ablating the progenitors, caused reduction of cHCC-CCA tumors but did not affect HCCs. RNA-sequencing revealed enrichment of the IL-6 signaling pathway in cHCC-CCA tumors compared to HCC tumors. Single-cell RNA-sequencing (scRNA-seq) analysis revealed that IL-6 is expressed by immune and parenchymal cells during senescence, and that IL-6 is part of the senescence-associated secretory phenotype. Administration of an anti-IL-6 antibody to Mdr2-KOFoxl1-CRE;RosaYFP mice inhibited the development of cHCC-CCA tumors. Blocking IL-6 trans-signaling led to a decrease in the number and size of cHCC-CCA tumors, indicating their dependence on this pathway. Furthermore, the administration of a senolytic agent inhibited IL-6 and the development of cHCC-CCA tumors. CONCLUSION: Our results demonstrate that cHCC-CCA, but not HCC tumors, originate from HPCs, and that IL-6, which derives in part from cells in senescence, plays an important role in this process via IL-6 trans-signaling. These findings could be applied to develop new therapeutic approaches for cHCC-CCA tumors. LAY SUMMARY: Combined hepatocellular carcinoma-cholangiocarcinoma is the third most prevalent type of primary liver cancer (i.e. a cancer that originates in the liver). Herein, we show that this type of cancer originates in stem cells in the liver and that it depends on inflammatory signaling. Specifically, we identify a cytokine called IL-6 that appears to be important in the development of these tumors. Our results could be used for the development of novel treatments for these aggressive tumors.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Rosenberg N, Van Haele M, Lanton T, et al. Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling. J Hepatol. 2022. PMID: 35988690. doi:10.1016/j.jhep.2022.07.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。